Solasia Pharma K.K. (TSE: 4597)
Health Care · Biotechnology · JP
¥32.00
-3.03% today · -17.9% 1Y
Solasia Pharma K.K. (TSE: 4597) operates in the Biotechnology industry within the Health Care sector. The company is valued at $54.95M and employs 22 people.
Over the last twelve months the share price has lost 17.9%, trading between 21.00 and 42.00.
Tweenvest scores Solasia Pharma K.K. across four factors: quality 27/100, value 78/100, growth 41/100. Its strongest factor is value.
4597 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $54.95M
- Revenue (TTM)
- $2.39M
- P/E
- —
- EPS
- -3.42
- Dividend yield
- —
- Beta (5Y)
- 1.21
- 52-week high
- ¥42.00
- 52-week low
- ¥21.00
- Avg volume (3M)
- —
- Shares outstanding
- 273.01M
- Employees
- 22
- Next earnings
- —
About Solasia Pharma K.K.
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
- ISIN
- JP3436500007
- Founded
- 2006
- Listed since
- Mar 27, 2017
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.